Recent developments in high-risk Myelodysplastic Neoplasms (HR MDS) treatment are
confronted with challenges in study design due to evolving drug combinations with …

The guidelines for classification, prognostication, and response assessment of
myelodysplastic syndromes/neo-plasms (MDS) have all recently been updated. In this report …

Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway
improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b …

Abstract The ACE-536-MF-001 trial enrolled patients with myelofibrosis (n= 95) into 4
cohorts: patients in cohorts 1 and 3A were non–transfusion dependent (NTD) and had …

Iron overload (IOL) is hypothesized to contribute to dysplastic erythropoiesis. Several
conditions, including myelodysplastic syndrome, thalassemia and sickle cell anemia, are …

Myelodysplastic syndrome and acute myeloid leukemia (AML) belong to a continuous
disease spectrum of myeloid malignancies with poor prognosis in the relapsed/refractory …

Reactive oxygen species (ROS) serve as typical metabolic byproducts of aerobic life and
play a pivotal role in redox reactions and signal transduction pathways. Contingent upon …

In patients with lower‐risk myelodysplastic syndromes/neoplasms (MDS), response to first‐
line therapy is limited and transient. The MATTERHORN randomized, double‐blind, phase 3 …

The myelodysplastic syndromes (MDS) constitute a profoundly heterogeneous myeloid
malignancy with a common origin in the hemopoietic stem cell compartment. Consequently …

Background The preplanned interim analysis of the COMMANDS trial showed greater
efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating …